The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_004360.4(CDH1):c.1849G>A (p.Ala617Thr)

CA121991

12232 (ClinVar)

Gene: CDH1
Condition: CDH1-related diffuse gastric and lobular breast cancer
Inheritance Mode: Autosomal dominant inheritance
UUID: 8fe2e0a3-670f-4cdb-bbf8-3836f7fc45e9

HGVS expressions

NM_004360.4:c.1849G>A
NM_004360.4(CDH1):c.1849G>A (p.Ala617Thr)
NC_000016.10:g.68822138G>A
CM000678.2:g.68822138G>A
NC_000016.9:g.68856041G>A
CM000678.1:g.68856041G>A
NC_000016.8:g.67413542G>A
NG_008021.1:g.89847G>A
ENST00000261769.10:c.1849G>A
ENST00000261769.9:c.1849G>A
ENST00000422392.6:c.1666G>A
ENST00000562836.5:n.1920G>A
ENST00000566510.5:c.*515G>A
ENST00000566612.5:c.*89G>A
ENST00000611625.4:c.1912G>A
ENST00000612417.4:c.1830+19G>A
ENST00000621016.4:c.1849G>A
NM_004360.3:c.1849G>A
NM_001317184.1:c.1666G>A
NM_001317185.1:c.301G>A
NM_001317186.1:c.-117G>A
NM_004360.5:c.1849G>A
NM_001317184.2:c.1666G>A
NM_001317185.2:c.301G>A
NM_001317186.2:c.-117G>A
NM_004360.5(CDH1):c.1849G>A (p.Ala617Thr)

Benign

Met criteria codes 1
BA1
Not Met criteria codes 25
PS2 PS4 PS3 PS1 PP4 PP1 PP2 PP3 PM3 PM1 PM4 PM5 PM6 PM2 PVS1 BS2 BS4 BS3 BS1 BP2 BP3 BP1 BP4 BP5 BP7

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen CDH1 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3.1

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
CDH1 VCEP
The c.1849G>A (p.Ala617Thr) variant has an allele frequency of 0.04479 (4.5%, 1,076/24,022 alleles) in the African subpopulation of the gnomAD cohort (BA1). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1.
Met criteria codes
BA1
1000 Genomes: 5.144% in AFR G: 0.94856 (1254) A: 0.05144 (68) ExAC: 4.622% in African (Allele count 481, 15 homozygotes) ESP6500: African American 4.709% (207)
Not Met criteria codes
PS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP3
Does not meet Impact Threshold: REVEL, SIFT, PolyPhen2-HVAR, MutationTaster, MutationAssessor, FATHMM, PROVEAN, MetaSVM, MetaLR, CADD Splicing predictors (conflicting): HSF: "Alteration of an exonic ESE site. Potential alteration of splicing" MaxEntScan: GATgCAGAC (reference) MAXENT: -12.96 GATACAGAC (this Variant) MAXENT: -21.14 NNSPLICE: No new donor/acceptor site predicted due to c.1849G>A
PM3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM6
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM2
1000 Genomes: 5.144% in AFR G: 0.94856 (1254) A: 0.05144 (68) ExAC: 4.622% in African (Allele count 481, 15 homozygotes) ESP6500: African American 4.709% (207)
PVS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
1000 Genomes: 5.144% in AFR G: 0.94856 (1254) A: 0.05144 (68) ExAC: 4.622% in African (Allele count 481, 15 homozygotes) ESP6500: African American 4.709% (207)
BP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
Does not meet Impact Threshold: REVEL, SIFT, PolyPhen2-HVAR, MutationTaster, MutationAssessor, FATHMM, PROVEAN, MetaSVM, MetaLR, CADD Splicing predictors (conflicting): HSF: "Alteration of an exonic ESE site. Potential alteration of splicing" MaxEntScan: GATgCAGAC (reference) MAXENT: -12.96 GATACAGAC (this Variant) MAXENT: -21.14 NNSPLICE: No new donor/acceptor site predicted due to c.1849G>A
BP5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP7
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Approved on: 2023-08-08
Published on: 2023-08-08
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.